BioLargo, Inc.
BLGO
$0.16
$0.00-1.82%
OTC PK
| 12/31/2025 | 09/30/2025 | ||||
|---|---|---|---|---|---|
| Revenue | -44.06% | -60.28% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -44.06% | -60.28% | |||
| Cost of Revenue | -33.11% | -46.09% | |||
| Gross Profit | -65.59% | -73.82% | |||
| SG&A Expenses | -50.04% | 158.07% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -44.30% | 80.89% | |||
| Operating Income | 44.33% | -298.45% | |||
| Income Before Tax | 42.82% | -284.91% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 42.82% | -284.91% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | 55.42% | 10.87% | |||
| Net Income | 54.42% | -443.54% | |||
| EBIT | 44.33% | -298.45% | |||
| EBITDA | 44.53% | -301.01% | |||
| EPS Basic | 55.24% | -438.46% | |||
| Normalized Basic EPS | 63.93% | -662.50% | |||
| EPS Diluted | 55.24% | -438.46% | |||
| Normalized Diluted EPS | 63.93% | -662.50% | |||
| Average Basic Shares Outstanding | 1.72% | 1.91% | |||
| Average Diluted Shares Outstanding | 1.72% | 1.91% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||